Page 3 - கூட்டாட்சியின் மருந்தகம் ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

endIndex: (CNN) Johnson & Johnson said Thursday it still expects to meet its commitments for the promised delivery of an additional 24 million doses of its COVID-19 vaccine in April, even after a quality problem at one of the company s contract manufacturers. The plant that had the problem, run by Baltimore-based Emergent BioSolutions, has not yet been authorized by the US Food and Drug Administration to make the vaccine and has not made any of the doses that are in the current vaccine rollout. Emergent told CNN the problem affected a single batch of bulk drug substance used to make vaccine. In an emailed statement to CNN, Emergent said its quality control systems caught the batch that did not meet specifications and our rigorous quality standards before it got any further. The company said it isolated the material and will now dispose of it.

New yorkUnited statesWhite houseDistrict of columbiaGrand riverLori freemanBob kramerJohnson baltimoreJennifer katesAnthony fauciCity health officialsDialysis centersNational institute of allergyDrug administrationKaiser family foundationCommunity health centers